QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia

The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination. The main questions it aims to answer are: * How many participants achieve measurable residual disease (MRD) negativity after 9 treatment cycles? * What side effects occur during treatment with QLS4131 combined with isatuximab? * How many participants respond to treatment, and how many achieve a c

Trial Details

NCT ID
NCT07903623
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • QLS4131
  • Isatuximab
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Participants must understand the study requirements and voluntarily provide written informed consent.
  • Age between 18 and 75 years.
  • Newly diagnosed primary plasma cell leukemia (pPCL) according to International Myeloma Working Group (IMWG) criteria, defined as malignant plasma c…
  • Measurable disease meeting at least one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →